Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Research and Innovation Action · Running

MARVAX Development of novel viral vectored vaccines against Marburgviruses inducing robust and cross-reactive protection

Coordinator
Bernhard-Nocht-Institut Fuer Tropenmedizin, Germany
Runs
1 December 2023 to 30 November 2027
Status
Running
EU funding
€7.4m
Total cost
€7.4m
Partners
4 organisations in 3 countries
Type
Research and Innovation Action
Grant agreement
101137183

What the project is doing

In the project's own words, from its summary on CORDIS.

The frequency, magnitude, and geographical range of Marburg virus disease outbreaks are expanding, with recent cases emerging in Equatorial Guinea and Tanzania. Marburgviruses, listed among the WHO priority pathogens, have demonstrated their epidemic potential. However, no licensed vaccines are available, and outbreaks continue to impose high morbidity and mortality burdens. Vaccine candidates in the pipeline are based on the Marburg virus (MARV) glycoprotein (GP) as a single immunogen.

MARVAX ambition is to improve the strength and breadth of MARV vaccines by deploying the measles virus (MV) and modified vaccinia virus Ankara (MVA) viral vector vaccine platforms for expression of several MARV antigens: GP, viral protein 40 (VP40), which together with GP allows the formation of virus-like particles, and the nucleoprotein (NP), which contains conserved epitopes that are the main drivers of T cell responses.

We will evaluate in depth the innate, adaptive and memory antigen-specific humoral and cellular cross-protective immune responses induced by MV-MARV and MVA-MARV vaccine candidates against MARV, Ravn virus and ebolaviruses, in single dose and in homologous and heterologous prime/boost immunization regimens, through an innovative preclinical testing pipeline. We will use cutting-edge and novel in vitro primary human cell co-cultures and immunocompetent mouse models to evaluate immunogenicity, chimeric and avatar mouse models to evaluate immunogenicity and efficacy and identify correlates of protection, and the highly relevant cynomolgus macaque model to evaluate safety, immunogenicity and efficacy.

Furthermore, GMP batches of the best vaccine candidates will be produced by the end of the project, towards their future evaluation in a phase I clinical trial, in collaboration with the WHO-led initiative for prioritization and acceleration of clinical trials of Marburgvirus vaccines in at-risk and healthcare communities and upon outbreaks.

Topics

Who is involved

OrganisationCityCountryRole
Bernhard-Nocht-Institut Fuer TropenmedizinHamburgGermanyCoordinator
Agencia Estatal Consejo Superior De Investigaciones CientificasMadridSpainParticipant
Cz Vaccines SAPorrinoSpainParticipant
Institut PasteurParisFranceParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI